8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 19, 2026·SEC
Material company update
Jan 7, 2026·SEC
Processa Pharmaceuticals, Inc.(PCSA)Earnings, Financials & Key Ratios
PCSA•NASDAQ
$1.89
Price updated Jul 7, 2026
AboutProcessa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.Show more
- Revenue$0
- EBITDA-$14M-16.1%
- Net Income-$14M-14.5%
- EPS (Diluted)-10.36+89.3%
- ROE-372.97%-5.2%
PCSA Price & Volume
Processa Pharmaceuticals, Inc. (PCSA) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Future Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Critical liquidity and funding
Key Thesis Takeaways
- Processa Pharmaceuticals remains a pre-revenue biotechnology entity characterized by a high-fixed cost structure, with quarterly R&D expenditures consistently ranging between $1.3 million and $2.4 million.
- The company's reliance on external capital to fund its clinical pipeline has led to significant shareholder dilution, evidenced by stock-based compensation reaching $431,000 in 2025Q2.
- Investors should monitor the critical liquidity position, as the current cash balance of $1.7 million against a history of multi-million dollar quarterly losses suggests an urgent need for additional financing.
Verdict Logic
the company's rapid depletion of resources, evidenced by total assets contracting from $9.9 million in 2024Q1 to $4.5 million in 2026Q1, presents a high risk of further equity dilution.
PCSA Growth Metrics
Processa Pharmaceuticals, Inc. (PCSA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-17.97%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM86.14%
Return on Capital
10 Years-281.95%
5 Years-218.74%
3 Years-307.43%
Last Year-384.62%
Peers Comparison
Key metrics vs top competitors for Processa Pharmaceuticals, Inc. (PCSA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.89 | $4.28M | -0.18 | — | — | -372.97% | — | |
| $4.34 | $17.12M | -0.17 | — | — | -381.01% | — | |
| $5.67 | $1.97B | -9.45 | 698.96% | -102.06% | -44.1% | — | |
| $15.63 | $1.31B | -29.49 | — | — | -38.92% | — | |
| $0.15 | $2.33M | -0.06 | -15.77% | -183.93% | — | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — |
Compare PCSA vs Peers
Processa Pharmaceuticals, Inc. (PCSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PCSA SEC Filings & Documents
Processa Pharmaceuticals, Inc. (PCSA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PCSA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PCSA Frequently Asked Questions
Processa Pharmaceuticals, Inc. (PCSA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is PCSA profitable?
Processa Pharmaceuticals, Inc. (PCSA) reported a net loss of $14.1M for fiscal year 2025.
Dividend & Returns
What is PCSA's return on equity?
Processa Pharmaceuticals, Inc. (PCSA) has a return on equity (ROE) of -373.0%. Negative ROE indicates the company is unprofitable.
What is Processa Pharmaceuticals, Inc.'s free cash flow?
Processa Pharmaceuticals, Inc. (PCSA) had negative free cash flow of $12.2M in fiscal year 2025, likely due to heavy capital investments.